US Health Resource Utilization and Cost Burden Associated with Choroideremia

Shaobin Dong,1 Nicole Tsao,2 Qiang Hou,1 Duygu Bozkaya,1 Bart P Leroy3– 5 1Value and Access, Biogen, Cambridge, MA, USA; 2Medical Health Outcomes and Research, Biogen, Cambridge, MA, USA; 3Department of Ophthalmology & Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; 4Depa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dong S, Tsao N, Hou Q, Bozkaya D, Leroy BP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	vision loss inherited retinal dystrophy claims data health economics Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/5a224d5ba1ae4d9aa385f41d82c0c681
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a224d5ba1ae4d9aa385f41d82c0c681
record_format	dspace
spelling	oai:doaj.org-article:5a224d5ba1ae4d9aa385f41d82c0c6812021-12-02T18:50:45ZUS Health Resource Utilization and Cost Burden Associated with Choroideremia1177-5483https://doaj.org/article/5a224d5ba1ae4d9aa385f41d82c0c6812021-08-01T00:00:00Zhttps://www.dovepress.com/us-health-resource-utilization-and-cost-burden-associated-with-choroid-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Shaobin Dong,1 Nicole Tsao,2 Qiang Hou,1 Duygu Bozkaya,1 Bart P Leroy3– 5 1Value and Access, Biogen, Cambridge, MA, USA; 2Medical Health Outcomes and Research, Biogen, Cambridge, MA, USA; 3Department of Ophthalmology & Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; 4Department of Head & Skin, Ghent University, Ghent, Belgium; 5Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USACorrespondence: Shaobin DongValue and Access, Biogen, 225 Binney Street, Cambridge, MA, 02142, USATel +1-857-331-5246Email shaobin.dong@biogen.comPurpose: Choroideremia is a progressive, inherited retinal dystrophy that leads to blindness. This study of choroideremia addresses health resource utilization (HRU) and costs from a US payor perspective using insurance claims data. The retrospective analysis used data between January 2013 and December 2018 from the IBM MarketScan Commercial, Medicare Supplemental, and Multi-State Medicaid Databases.Patients and Methods: Patients having ≥ 1 claim with an International Classification of Diseases, Ninth or Tenth Edition, diagnostic code for choroideremia (363.55/H31.21) were included; a control group was matched 3:1 to the choroideremia group. Patients were followed for ≥ 6 months. All-cause HRU and costs were compared between cohorts using generalized linear models adjusted for Charlson Comorbidity Index.Results: There were 199 and 597 patients in the choroideremia and control groups, respectively; the choroideremia group had a higher mean baseline Charlson Comorbidity Index (0.47 vs 0.26). The choroideremia group had a significantly greater mean number of hospital admissions (0.09 vs 0.06), outpatient visits (22.33 vs 11.22), and emergency department visits (0.41 vs 0.26) per patient per year than the control group. The choroideremia cohort had higher all-cause total annualized costs than the control cohort ($15,372 vs $9285), primarily driven by outpatient visits ($8306 vs $4702). This trend was observed across age categories, particularly among patients aged 20 to 44 years (choroideremia, $14,544 vs control, $5953).Conclusion: The choroideremia group had higher all-cause HRU and total costs versus the control group. These findings provide economic context around HRU associated with choroideremia and help assess the potential impact of novel treatments.Keywords: vision loss, inherited retinal dystrophy, claims data, health economicsDong STsao NHou QBozkaya DLeroy BPDove Medical Pressarticlevision lossinherited retinal dystrophyclaims datahealth economicsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3459-3465 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	vision loss inherited retinal dystrophy claims data health economics Ophthalmology RE1-994
spellingShingle	vision loss inherited retinal dystrophy claims data health economics Ophthalmology RE1-994 Dong S Tsao N Hou Q Bozkaya D Leroy BP US Health Resource Utilization and Cost Burden Associated with Choroideremia
description	Shaobin Dong,1 Nicole Tsao,2 Qiang Hou,1 Duygu Bozkaya,1 Bart P Leroy3– 5 1Value and Access, Biogen, Cambridge, MA, USA; 2Medical Health Outcomes and Research, Biogen, Cambridge, MA, USA; 3Department of Ophthalmology & Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; 4Department of Head & Skin, Ghent University, Ghent, Belgium; 5Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USACorrespondence: Shaobin DongValue and Access, Biogen, 225 Binney Street, Cambridge, MA, 02142, USATel +1-857-331-5246Email shaobin.dong@biogen.comPurpose: Choroideremia is a progressive, inherited retinal dystrophy that leads to blindness. This study of choroideremia addresses health resource utilization (HRU) and costs from a US payor perspective using insurance claims data. The retrospective analysis used data between January 2013 and December 2018 from the IBM MarketScan Commercial, Medicare Supplemental, and Multi-State Medicaid Databases.Patients and Methods: Patients having ≥ 1 claim with an International Classification of Diseases, Ninth or Tenth Edition, diagnostic code for choroideremia (363.55/H31.21) were included; a control group was matched 3:1 to the choroideremia group. Patients were followed for ≥ 6 months. All-cause HRU and costs were compared between cohorts using generalized linear models adjusted for Charlson Comorbidity Index.Results: There were 199 and 597 patients in the choroideremia and control groups, respectively; the choroideremia group had a higher mean baseline Charlson Comorbidity Index (0.47 vs 0.26). The choroideremia group had a significantly greater mean number of hospital admissions (0.09 vs 0.06), outpatient visits (22.33 vs 11.22), and emergency department visits (0.41 vs 0.26) per patient per year than the control group. The choroideremia cohort had higher all-cause total annualized costs than the control cohort ($15,372 vs $9285), primarily driven by outpatient visits ($8306 vs $4702). This trend was observed across age categories, particularly among patients aged 20 to 44 years (choroideremia, $14,544 vs control, $5953).Conclusion: The choroideremia group had higher all-cause HRU and total costs versus the control group. These findings provide economic context around HRU associated with choroideremia and help assess the potential impact of novel treatments.Keywords: vision loss, inherited retinal dystrophy, claims data, health economics
format	article
author	Dong S Tsao N Hou Q Bozkaya D Leroy BP
author_facet	Dong S Tsao N Hou Q Bozkaya D Leroy BP
author_sort	Dong S
title	US Health Resource Utilization and Cost Burden Associated with Choroideremia
title_short	US Health Resource Utilization and Cost Burden Associated with Choroideremia
title_full	US Health Resource Utilization and Cost Burden Associated with Choroideremia
title_fullStr	US Health Resource Utilization and Cost Burden Associated with Choroideremia
title_full_unstemmed	US Health Resource Utilization and Cost Burden Associated with Choroideremia
title_sort	us health resource utilization and cost burden associated with choroideremia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/5a224d5ba1ae4d9aa385f41d82c0c681
work_keys_str_mv	AT dongs ushealthresourceutilizationandcostburdenassociatedwithchoroideremia AT tsaon ushealthresourceutilizationandcostburdenassociatedwithchoroideremia AT houq ushealthresourceutilizationandcostburdenassociatedwithchoroideremia AT bozkayad ushealthresourceutilizationandcostburdenassociatedwithchoroideremia AT leroybp ushealthresourceutilizationandcostburdenassociatedwithchoroideremia
_version_	1718377504104775680

US Health Resource Utilization and Cost Burden Associated with Choroideremia

Ejemplares similares